

Andrews Kurt J.  
Form 3  
September 27, 2018

# FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*

^ Andrews Kurt J.

(Last) (First) (Middle)

C/O IMMUNOMEDICS, ^ 300  
THE AMERICAN ROAD

(Street)

MORRIS PLAINS, ^ NJ ^ 07950

(City) (State) (Zip)

2. Date of Event Requiring Statement

(Month/Day/Year)

09/24/2018

3. Issuer Name and Ticker or Trading Symbol  
IMMUNOMEDICS INC [IMMU]

4. Relationship of Reporting Person(s) to Issuer

5. If Amendment, Date Original Filed(Month/Day/Year)

(Check all applicable)

\_\_\_ Director \_\_\_ 10% Owner

☒ X \_\_\_ Officer \_\_\_ Other

(give title below) (specify below)

CHIEF HUMAN RESOURCES  
OFFICER

6. Individual or Joint/Group

Filing(Check Applicable Line)

☒ X \_\_\_ Form filed by One Reporting Person

\_\_\_ Form filed by More than One Reporting Person

### Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security  
(Instr. 4)

2. Amount of Securities Beneficially Owned  
(Instr. 4)

3. Ownership Form:  
Direct (D)  
or Indirect (I)  
(Instr. 5)

4. Nature of Indirect Beneficial Ownership  
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

### Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security  
(Instr. 4)

2. Date Exercisable and Expiration Date  
(Month/Day/Year)

Date Exercisable Expiration Date

3. Title and Amount of Securities Underlying Derivative Security  
(Instr. 4)

Title Amount or Number of Shares

4. Conversion or Exercise Price of Derivative Security

5. Ownership Form of Derivative Security:  
Direct (D)  
or Indirect (I)

6. Nature of Indirect Beneficial Ownership  
(Instr. 5)

(Instr. 5)

Stock Option (right to buy)	07/11/2019 <sup>(1)</sup>	07/11/2025	Common Stock, par value \$0.01 per share	76,222	\$ 24.76	D	Â
-----------------------------	---------------------------	------------	--	--------	----------	---	---

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Andrews Kurt J. C/O IMMUNOMEDICS 300 THE AMERICAN ROAD MORRIS PLAINS, NJ 07950	Â	Â	Â CHIEF HUMAN RESOURCES OFFICER	Â

## Signatures

/s/ Kurt Andrews	09/27/2018
<u>    </u> Signature of Reporting Person	Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The reporting person was granted stock options pursuant to the Company's 2014 Long-Term Incentive Plan. The stock options vest 25% on the first anniversary of the date of grant and 2.08333% on a monthly basis thereafter.

Â

### Remarks:

OnÂ SeptemberÂ 24,Â 2018,Â theÂ IssuerÂ appointedÂ theÂ ReportingÂ PersonÂ asÂ theÂ Issuer'sÂ ChiefÂ HumanÂ Res

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.